抗癌活性肽对人胃癌BGC-823细胞周期的调控  

Regulation of ACBP on cell cycle of human stomch cancer cell BGC-823

作　　者：徐桂华[1] 苏秀兰[1] 申杰[1] 毕力夫[2] 欧阳晓晖[3] 

机构地区：[1]内蒙古医学院临床医学研究中心,内蒙古呼和浩特010050 [2]内蒙古医学院卫生学系,内蒙古呼和浩特010059 [3]内蒙古医学院第一附属医院普外科,内蒙古呼和浩特010050

出　　处：《中华肿瘤防治杂志》2007年第18期1361-1364,共4页Chinese Journal of Cancer Prevention and Treatment

基　　金：国家自然科学基金(30460146);内蒙古自治区教育厅重大项目(ZD9809)

摘　　要：目的:探讨抗癌活性肽(anti-cancer bioactive peptide,ACBP)对人胃癌细胞BGC-823细胞周期的影响及其作用机制。方法:体外培养BGC-823细胞,将不同浓度的ACBP作用于细胞,MTT法测定不同浓度的ACBP对BGC-823细胞的生长抑制率;HE染色观察形态学变化;半定量RT-PCR检测细胞周期负性调控分子p27基因mRNA表达的变化。结果:不同浓度(10.0～25.0mg/L)ACBP均能抑制BGC-823细胞的生长,细胞出现明显的凋亡特征性改变,且具有浓度和时间依赖性,25.0mg/LACBP作用72h抑制率为(84.4±2)%,中效浓度(IC50)为7.86mg/L。RT-PCR发现经ACBP处理后,BGC-823细胞的p27mRNA表达明显增加。结论:ACBP对BGC-823细胞的生长有明显的抑制作用,并可诱导细胞凋亡,其抑癌机制可能与其调控细胞周期有关,使p27mRNA重获表达,从而发挥抗BGC-823细胞增殖的作用。OBJECTIVE： To explore the regulation and mechanism of action of anti-cancer bioactive peptide （ACBP） on cell cycle of human stomach cancer cell line BGC-823. METHODS： BGC-823 cells were cultured with different concentrations of ACBP in vitro. The MTT method was employed to measure the growth inhibition rates at different concentrations of ACBP; the morphological changes were observed under the light microscope by HE staining; the semi-quantitative RT-PCR was used to assay the changes of p27 mRNA expression. RESULTS： Different concentrations of ACBP in the range of 10.0- 25.0 mg/L inhibited the growth of BGC-823 cell and showed both concentration and time dependent. The concentration of ACBP at 25.0 mg/L had an inhibition rate of （84.4 ± 2）% and a median concentration （IC50） of 7.86 mg/L at 72 h, and the cells showed typical apoptotic changes under the light microscope. On RT-PCR, the expression of p27 mRNA in BGC-823 cell was markedly increased after ACBP treated. CONCLUSIONS： ACBP has significantly inhibiting effects on the growth of BGC-823 cell. The mechanism is probably related to its regulatory effects on cell cycle and re-expression of p27 mRNA. Thus the anti-proliferative action is achieved.

关 键 词：肽类 胃肿瘤 基因产物 

分 类 号：R735.2[医药卫生—肿瘤]